Oral Semaglutide: 4-Month Study

A 2026 prospective observational study followed 70 adults with obesity but without diabetes after they started oral semaglutide in routine clinical care. After four months, mean body weight was 5.4 kg lower. The researchers reported that most of the change came from fat mass, while lean mass fell slightly and muscle strength remained unchanged^[1].

The result offers a short real-world view of oral semaglutide in people outside its type 2 diabetes indication. The study had no comparison group. It therefore cannot show that the medicine caused every observed change. A later published comment names this study, but PubMed supplies no abstract or full comment text, so its authors' specific criticisms cannot be reported from the accessible record^[3].

How the oral semaglutide study worked

Researchers at several centers enrolled 70 adults who had obesity without diabetes and had started oral semaglutide as part of routine care. The report describes the project as prospective, meaning outcomes were followed forward after enrollment, and observational, meaning the researchers did not randomly assign treatment. The abstract does not provide the recruitment setting, participant ages, sex distribution or attrition count^[2].

The main objective was to examine changes in body weight, body composition and muscle strength. Secondary objectives covered metabolic measures, inflammatory markers and depressive symptoms. The public abstract says the medicine was used at doses approved for type 2 diabetes, but it does not list the dose distribution or describe how treatment changed during follow-up^[2]. That evidence gap matters because readers cannot reconstruct the care protocol from the indexed record.

This article reports the study rather than turning it into a dosing guide. Oral semaglutide is a prescription medicine, and a four-month observational result cannot determine an appropriate treatment plan for an individual.

Weight fell mainly through fat mass

At four months, participants had lost 5.4 kg on average. The authors attribute most of the change to lower fat mass and also report decreases in waist circumference and visceral fat. The indexed abstract does not provide confidence intervals, baseline weight or the separate numerical changes for those body-composition measures. Without them, the precision and clinical spread around the 5.4 kg mean cannot be assessed from the accessible text^[2].

The study also reported that 44.3% of participants reached what its authors called clinically meaningful weight loss. The threshold definition is missing. We therefore cannot translate the percentage into a specific cutoff. A mean change and a threshold proportion answer different questions: one summarizes the group, while the other counts people who crossed a prespecified line. The missing definition limits interpretation of the 44.3% figure^[2].

These findings sit within the broader semaglutide evidence overview, which includes randomized trials of other semaglutide formulations and indications. Results from those programs should not be merged with this small oral-semaglutide cohort. Different formulations, populations and study designs can produce different estimates.

Lean mass dipped while strength held steady

Lean mass showed a small reduction over four months, while measured muscle strength did not change, according to the abstract. Lean mass covers more than skeletal muscle and can shift with body water and other tissues. Because the indexed record does not name the body-composition instrument or strength test, it cannot show how sensitive either measure was to small changes^[2].

Stable group-average strength over four months is reassuring within the narrow limits of this cohort. Individual results remain unknown. The group mean does not establish that every participant preserved strength, that no muscle tissue was lost or that the same pattern would continue during longer treatment. Those questions require participant-level results, a clearly described measurement method and longer follow-up.

The authors also report improvements in metabolic parameters, inflammatory markers and depressive symptoms. The accessible abstract does not identify the individual measures or give effect sizes, variability or statistical comparisons. Reporting a direction without those figures is not enough to judge the size or reliability of each secondary change^[2].

The study cannot establish semaglutide's effect

With no comparison group, the study cannot separate the medicine's contribution from changes in diet, activity, concurrent care or regression toward typical values after an unusually high baseline measurement. Prospective follow-up improves the timing of data collection, yet it does not remove confounding when treatment was not randomized.

Follow-up lasted only four months. With 70 participants, the study had limited room to assess uncommon harms, long-term weight maintenance or outcomes after treatment stops. The abstract does not report adverse events, discontinuations or missing follow-up. Silence in an abstract does not mean that no adverse events occurred. It means the accessible record cannot support a safety estimate for this cohort.

The later comment by Xue Huang and Jie Zhou was published online on 28 July 2026 as a letter in Medicina Clínica. Its title directly identifies the Nicolau, Dotres and Blanco-Anesto study, and Crossref lists that original paper among the comment's references. PubMed and Europe PMC expose metadata but no comment abstract, while the publisher text was not accessible in this review^[3]. The full argument remains unavailable. We therefore do not assign any methodological objection or conclusion to the comment authors.

What we still need to know

A stronger follow-up would disclose the body-composition and strength methods, account for every enrolled participant and report numerical changes with uncertainty intervals. A comparator group would help estimate how much change tracked with oral semaglutide rather than other parts of care. Longer follow-up would show whether fat loss, lean-mass change and strength remained stable.

The current paper supports a limited conclusion. In this 70-person cohort, body weight was lower after four months, most of the reported change came from fat mass, and average muscle strength was unchanged. The design supports an association over time. It cannot prove a treatment effect or predict what one person will experience.

Readers considering the medicine can review the semaglutide safety summary and discuss formulation, indication and monitoring with a qualified clinician. The study's dose context should not be copied into self-directed treatment.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.